Promente Clinical Research Center
Cooperation
Information about cooperation and clinical research.
Basic study information
For many people, antidepressant medicines do not provide the expected improvement. A condition in which at least two antidepressant treatments are not sufficiently effective is described as treatment-resistant depression.
COMP360 is a synthetic form of psilocybin. It is studied together with psychological support as a potential approach to symptoms of treatment-resistant depression.
Who may participate?
- Adults diagnosed with treatment-resistant depression.
- People for whom at least two antidepressant medicines have not been sufficiently effective.
Additional information
Detailed information about study conduct and eligibility is available directly from the clinical research site.